相关实验视频

Updated: Jul 4, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

药物治疗后痛风爆发的风险:处方对称序列分析

Shih-Wei Lai^1,2, Bing-Fang Hwang³, Yu-Hung Kuo⁴

¹Department of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.

Clinical rheumatology

|February 2, 2024

概括

这项研究发现,某些药物,如阿司匹林和利尿剂增加了痛风发作风险,而 fenofibrate 和 losartan 可能会提供保护. 甲胺使用也显示出更高的痛风爆发的可能性,这需要进一步调查.

科学领域:

药物监督和药物流行病学
药物安全和不良事件检测.
痛风管理和治疗方法

背景情况:

处方对称序列分析 (PSSA) 是确定药物不良反应的既定方法.
众所周知,几种药物会导致痛风发作,这对临床来说是一个挑战.
了解药物诱导的痛风发作对于患者的安全和有效治疗至关重要.

研究的目的:

通过使用来自台湾的真实世界数据,验证PSSA在识别痛风相关药物不良事件中的有效性.
调查9种选定的药物与痛风爆发的相关性.
探索某些药物对痛风爆发的潜在保护作用.

主要方法:

利用台湾国家健康保险计划数据 (2003-2017) 涵盖200万受益人.
采用药物诱导的痛风爆发场景,通过使用标记剂来定义痛风爆发.
应用PSSA来比较索引剂和标记剂处方的序列,计算调整的序列比率 (调整的SR).

主要成果:

五种药物 (阿司匹林, thiazide 利尿剂,循环利尿剂, ethambutol, pyrazinamide) 显示出具有统计学意义的关联与增加的痛风爆发概率 (调整 SR 1.153.35).
费诺纤维酸和洛萨坦的使用与痛风爆发的可能性降低有关 (调整后的SR分别为0.60和0.92).
甲胺使用与更高的痛风发作概率相关 (调整后的SR为1.14),而皮奥格利塔没有达到统计学意义.

结论:

PSSA 是一种有效的方法来检测药物不良事件,特别是药物诱导的痛风爆发.
费诺纤维酸和洛萨坦可以作为抗痛风爆发的保护剂.
甲胺的使用值得进一步研究,因为它与痛风发作风险增加有关.

关键词:

阿司匹林是一种阿司匹林.甲状腺炎的爆发.循环利尿剂循环利尿剂处方对称性序列分析铁酸性利尿剂是什么

更多相关视频

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Synovial Fluid Analysis to Identify Osteoarthritis

Synovial Fluid Analysis to Identify Osteoarthritis

Published on: October 20, 2022

相关概念视频

Phase II Reactions: Glucuronidation

Phase II Reactions: Glucuronidation

Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...

Drug Metabolism: Phase II Reactions

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...